Base Ten Systems Receives Purchase Order for First Two Akzo Nobel Pharma Manufacturing Plants Under Global Purchase Agreement; Contract Awards More Than $1 Million to Base Ten.

TRENTON, N.J.--(BW HealthWire)--July 6, 1999--

Base Ten Systems, Inc. (Nasdaq:BASEA) (the "Company") announced today that it has received a purchase order to supply its BASE10(TM) Manufacturing Execution Systems (BASE10(TM) ME) software products and services to the first two manufacturing plants of Akzo Nobel pharmaceutical business units.

The total amount of the contract is in excess of $1 million. The first plants to implement BASE10(TM) ME are Diosynth B.V. and NV Organon, both located in Oss, the Netherlands.

Thomas E. Gardner, chairman and chief executive officer of Base Ten Systems, said: "We are very pleased to have begun implementing our global agreement with Organon and Diosynth. The Diosynth and Organon plants represent the first of many opportunities to demonstrate the ability of our core BASE10(TM) ME technology to provide our worldwide customers with more cost-effective regulatory compliance, improved manufacturing flexibility and a reduced production cycle."

Diosynth will implement the BASE10(TM) ME package as a stand-alone system for the tracking and tracing of all materials, containers, equipment and personnel in a dock-to-dock multi-purpose plant in Oss, The Netherlands. The system will be up and running in October 1999.

NV Organon will implement BASE10(TM) ME in its production site in Oss, The Netherlands. The new technology will cover Tablet Production, Parenterals Production, Materials Handling and Packaging. Also departments related to Production like Quality Assurance and Logistics are involved in this project. Completion of the implementation followed by a phased roll out is estimated at the end of 2001.

Base Ten also said that it has begun discussions to implement the BASE10(TM) CS Clinical Supplies Solution at the Organon Clinical Supplies Unit. BASE10(TM) CS will be integrated with BASE10(TM) ADLS drug labeling and materials management system for Clinical Supplies, which is already in use at Organon.

NV Organon and Diosynth B.V. are pharmaceutical business units of Akzo Nobel. Akzo Nobel, based in the Netherlands, serves customers throughout the world with healthcare products, coatings, chemicals, and fibers. The fibers business, now known as Acordis, will be demerged. The company currently employs approximately 86,000 people and has activities in more than 70 countries.

Base Ten Systems is a software technology development company focused on manufacturing execution systems and services for the pharmaceutical, chemicals and medical products industries. Through installation of BASE10(TM) software, the Company's customers around the world can enjoy more cost-effective regulatory compliance, improved manufacturing flexibility and reduced production cycle time.

BASE10(TM) execution systems are readily integrated with complementary software partners as manufacturers consolidate their operations into global supply chain processes. Learn more about Base Ten Systems by visiting its web site at www.base10.com.

Forward-Looking Statement 

The foregoing contains "forward-looking information" within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements may be identified by the letter ("a") or by such forward-looking terminology as "may," "will," "believe," "anticipate," "expect," or similar words or variations thereof.

Such forward-looking statements involve certain significant risks and uncertainties.

Important factors that the Company believes may cause actual results to differ materially from such forward-looking statements are discussed in the "Risk Factors," "Business" and "MD&A" sections of the Company's current S-3 registration statements and annual and quarterly reports on file with the Securities and Exchange Commission.

Additional risk factors include the effectiveness of software and the ability of software to operate without "bugs" in the technology and acceptance of the release by customers and actual rollout. In assessing such forward-looking statements, investors are urged to read carefully those reports and other filings.

The Company does not undertake to publicly update or revise its forward-looking statements, even if experience or future changes indicate that any such results or event (expressed or implied) will not be realized.